New therapies, screening interventions offer hope for progress

ADD SUBJECT TO EMAIL MESSAGES

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published on. ” data-action=subscribe> Subscribe We were unable to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Helio

Cervical Cancer Awareness Month is observed every January.

Approximately 14,100 new cases of invasive cervical cancer are diagnosed in the United States annually, and approximately 4,280 women will die from the disease this year, according to the American Cancer Society.

Cervical Cancer Awareness Month helps educate the public about the highly preventable malignancy through HPV vaccination and proper screening.

In conjunction with surveillance, Healio provides the following updates on cervical cancer prevention, screening, diagnosis and treatment.

1. Treatment of advanced, recurrent and metastatic cervical cancer has come a long way in the past 15 years, and data on new combinations and therapies offer hope for further progress, according to a Chemotherapy Foundation symposium speaker. Read more.

2. Remote interventions led to higher rates of screening for cervical cancer and other malignancies among women living in rural areas. Read more.

3. Minimally invasive surgery yields lower survival rates than open surgery among women with cervical cancer, phase 3 study results show. Read more.

4. Evaluation of sexual function was performed much less often among women who underwent brachytherapy for cervical cancer than among men who received internal radiation therapy for prostate cancer. Read more.

5. Atezolizumab (Tecentriq, Genentech), given before and during chemoradiation therapy, appears safe and has demonstrated immunomodulatory activity among women with locally advanced, node-positive cervical cancer. Read more.

6. The rate of advanced cervical cancer increased among certain women in the United States between 2001 and 2018. At the same time, the rate of early-stage cervical cancer decreased. Read more.

7. Individuals who identify as a sexual minority were less likely than heterosexual individuals to have ever had a Pap test. Findings appear to be consistent across specific sexual minority groups. Read more.

8. The decline in cervical cancer in the United States among younger women may be related to the approval of HPV vaccination. Read more.

Reference: